Demographic, clinical and therapeutic characteristics of patients with rheumatoid arthritis admitted to the rheumatology service of the Dr. Arnulfo Arias Madrid, from January 2010 to September 2019
Article Sidebar
Main Article Content
Abstract
Introduction: Rheumatoid arthritis (RA) is the most common autoimmune rheumatological disease worldwide and according to the Global Burden of Diseases (GBD) 2010 study, out of the 291 conditions analyzed, it was ranked 42nd in the count of contributors to global disability and carries a global burden of disease measured in Disability Adjusted Life Years (DALYs) that has increased from 3.3 million in 1990 to 4.8 million in 2010.1
General objective: To describe the demographic, clinical characteristics and therapeutic approach of patients with RA admitted to the Rheumatology Service of the CHDRAAM, from January 1st, 2010 to September 30th, 2019.
Methodology: Descriptive, retrospective, cross-sectional study that included all patients over 18 years of age admitted with a diagnosis of RA.
Results: Five hundred and seven patients were studied, of which 90 % were female. Hypertension was the most frequent comorbidity (49 %) and the most common extra-articular manifestations were rheumatoid nodules (12 %). The secondary Sjögren’s syndrome was present in 10 %. Fifty three percent of the patients did not use glucocorticoids and the majority (47 %) were on dual therapy with conventional disease modifying antirheumatic drugs (cDMARDs). The most used combination was methotrexate + hydroxychloroquine (15 %) and the most common biological DMARD (bDMARDs) as a first option was the Etanercept (8.7 %).
Conclusion: Most of our patients are being managed with cDMARDs which represents safety and less costs for our health system.
Downloads
Article Details
Issue
Section
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
References
1. Cross M, Smith E, Hoy D, Carmona L, Wolfe F, Vos T, et al. The global burden of rheumatoid arthritis: estimates from the global burden of disease 2010 study. Ann Rheum Dis. 2014;73:1316-22.
2. Safiri S, Kolahi AA, Hoy D, Smith E, Bettampadi D, Mansournia MA, et al. Global, regional and national burden of rheumatoid arthritis 1990- 2017: a systematic analysis of the Global Burden of Disease study 2017. Ann Rheum Dis. 2019;78:1463-71.
3. Hochberg MC, Gravellese EM, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH, eds. Rheumatology, 7th edition. Philadelphia, PA: Elsevier; 2019.
4. Agca, R. et al. Cardiovascular Event Risk in Rheumatoid Arthritis is Higher than in Type 2 Diabetes: a 15 Year Longitudinal Study. J Rheumatol, 2019;46:1-20. 5. Ngo ST, Steyn FJ, McCombe PA. Gender differences in autoimmune disease. Front Neuroendocrinol. 2014;35:347-69.
6. Bautista-Molano W, et al. Perfil epidemiológico de pacientes colombianos con artritis reumatoide evaluados en la clínica especializada de atención integral. Reumatología clínica. 2016;12:313 -8.
7. de Lucena Valim JM, Gonçalves Chaer FG, Guimarães da Silveira FD, da Silva E Lima VP, Batista de Souza BD. Switching of biological therapies in Brazilian patients with rheumatoid arthritis. Future Sci OA. 2018 Dec 4;5(1):FSO355.
8. Dougados M, Soubrier M, Antunez A, Balint P, Balsa A, Buch MH, et al. Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, crosssectional study (COMORA). Ann Rheum Dis. 2014;73:62-8.
9. Ortega-Gómez A, Sanabria-Castro A, Alpízar-Campos R, Guerra-Bautista G, Méndez-Rodríguez J, Muñoz-Louis R, et al. Intravenous tocilizumab in the management of rheumatoid arthritis: Clinical practice findings from a 6 month international, multicentre, observational study in Central America and the Caribbean. Revista Colombiana de Reumatología. 2020;27:245-55.
10. Mahagna H, Caplan A, Watad A, Bragazzi NL, Sharif K, Tiosano S, et al. Rheumatoid arthritis and thyroid dysfunction: A cross-sectional study and a review of the literature. Best Pract Res Clin Rheumatol. 2018;32:683-91.
11. Anoop J, Geetha F, Jyothi I, Rekha P, Shobha V. Unravelling thyroid dysfunction in rheumatoid arthritis: History matters. Int J Rheum Dis. 2018;21:688-92.
12. Krishnan E, Sokka T, Hannonen P. Smoking-gender interaction and risk for rheumatoid arthritis. Arthritis Res Ther. 2003;5:R158-62.
13. Zhang XY, Jin JY, He J, Gan YZ, Chen JL, Zhao XZ, et al. [Family history of rheumatic diseases in patients with rheumatoid arthritis: a large scale cross-sectional study]. Beijing Da Xue Xue Bao Yi Xue Ban. 2019;51:439- 44.
14. Lutf A, Poil AR, Hammoudeh M. Characteristics of patients with rheumatoid arthritis in Qatar: a crosssectional study. International Journal of Rheumatic Diseases.2014;17:63-5.
15. Theander L, Nyhäll-Wåhlin BM, Nilsson JÅ, Willim M, Jacobsson LTH, Petersson IF, et al. Severe extraarticular manifestations in a Community-based cohort of patients with rheumatoid arthritis: risk factors and incidence in relation to treatment with tumor necrosis factor inhibitors. J Rheumatol. 2017;44(7):981–7.
16. Prete M, Racanelli V, Digiglio L, Vacca A, Dammacco F, Perosa F. Extra-articular manifestations of rheumatoid arthritis: An update. Autoimmun Rev. 2011;11:123-31.
17. Fautrel B, Cukierman G, Joubert JM, Laurendeau C, Gourmelen J, Fagnani F. Characteristics and management of rheumatoid arthritis in France: Analysis of a representative French national claims database resulting in an estimated prevalence of 0.35. Joint Bone Spine. 2016;83:461-2.
18. 1Ahsan T, Erum U, Khowaja D, Dahani A. Delayed conventional DMARDs therapy is effective in Rheumatoid Arthritis. Pak J Med Sci. 2017;33:840-3.